Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Article image or reusable cover for TechCrunch AI
The round valued the AI biotech at $2 billion.
It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Read the full story at TechCrunch AI →
The text is the source's own description of its publication. The content belongs to TechCrunch AI.
More from TechCrunch AI
Google froze its open source bug bounty program due to a ‘significant rise’ in AI submissions
TechCrunch AI 15 h ago
Can ‘super intelligence’ and a non-binding safety pact solve AI’s image problem?
TechCrunch AI 15 h ago
Trump unveils his new Super Intelligence Force
TechCrunch AI 20 h ago
Amazon responds to data center backlash, says it no longer uses NDAs
TechCrunch AI 3 Oct